Orsini Specialty Pharmacy and Zevra Therapeutics announced that Orsini is now the pharmacy partner for OLPRUVA for oral suspension. OLPRUVA is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinic acid synthetase.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
- Zevra Therapeutics files $350M mixed securities shelf
- Zevra Therapeutics Unveils Promising KP1077 Phase 2 Results
- Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
- Zevra Therapeutics announces final results from Phase 2 trial of KP1077